← Back to Home

Where Do Dormant Breast Cancer Cells Hide? Tumor Map Reveals a Possible Protective Environment

The study links breast cancer cells’ activity states to their locations, finding that dormant regions often contain specific immune cells and fibroblasts. This offers clues for investigating cancer cells that remain after treatment, but how the “protective shield” forms and whether it could become a therapeutic target still require experimental validation.

By SURL BioNews

One challenge in cancer treatment is how to eliminate cells that temporarily stop dividing but may become active again later. A breast cancer study has turned its attention to these quiet corners: researchers found that cancer cells with dormant characteristics often cluster in specific environments, with nearby immune cells and cells that support tissue potentially working together to provide conditions that allow them to persist.

The study was published in *Genome Medicine* on July 9, 2026, through a collaboration among teams from the UK Medical Research Council Laboratory of Medical Sciences, Imperial College London, and the University College London Genetics Institute, jointly led by Alexis Barr and Maria Secrier. The team integrated publicly available data, analyzing 138,727 cells from 43 breast cancer patients and 4 healthy individuals, along with 32,845 spatial measurement points in tissue, to map the distribution of different cell states within tumors.

Single-cell RNA sequencing shows which genes individual cells are using, while spatial transcriptomic analysis adds location information, allowing researchers to see the cells’ “neighbors.” The team developed a tumor-specific G0 gene expression signature and validated the classification method through experiments in breast cancer cell lines. G0 indicates that a cell has exited the division cycle; cells with characteristics of reversible dormancy are important subjects for research into treatment tolerance and recurrence.

The map showed that regions containing dormant cells were often close to CXCL10-positive macrophages and myofibroblast-type cancer-associated fibroblasts. The team also identified populations in pretreatment tumors with gene expression resembling that of treatment-tolerant cells, found in both more aggressive and slower-growing types of breast cancer. This suggests that tolerance-related characteristics may already exist before treatment begins.

However, describing the surrounding cells as a “protective shield” remains a mechanistic hypothesis. In an announcement from the research institution, Secrier noted that the direction of causality is still unclear: surrounding cells may prompt cancer cells to enter dormancy, or cancer cells may attract or alter neighboring cells. Spatial association alone is insufficient to prove that these cells actually block drugs or immune attacks.

Different regions also showed different biological signals. Dormant regions were associated with complement pathway activity; complement is part of the immune system. Proliferating regions were associated with CLEC9A-positive dendritic cells and PERK signaling. These differences suggest a direction that remains to be tested: if cells within the same tumor depend on different environments, future drug combinations may need to address proliferating cells, dormant cells, and their support systems simultaneously.

A substantial gap remains between locating these cells and treating them. This work primarily analyzed existing tumor data; it did not directly track how the identified cells evade treatment and subsequently cause recurrence, nor did it demonstrate that intervening in complement activity or surrounding support cells can improve patient outcomes. It provides a map for testing in subsequent experiments: understanding why cancer cells remain requires examining both the cells themselves and the environments they inhabit.

References

  1. ScienceDaily Top Health
  2. Genome Medicine
  3. MRC Laboratory of Medical Sciences